[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,802,831
  • Shares Outstanding, K 124,433
  • Annual Sales, $ 88,040 K
  • Annual Income, $ -784,960 K
  • EBIT $ -640 M
  • EBITDA $ -630 M
  • 60-Month Beta 0.42
  • Price/Sales 110.40
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 44.12% (-2.96%)
  • Historical Volatility 40.13%
  • IV Percentile 4%
  • IV Rank 1.99%
  • IV High 183.58% on 05/04/26
  • IV Low 41.30% on 06/12/26
  • Expected Move (DTE 27) 7.06 (8.96%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 838
  • Volume Avg (30-Day) 2,002
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 112,421
  • Open Int (30-Day) 103,959
  • Expected Range 71.73 to 85.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.64
  • Number of Estimates 8
  • High Estimate $-1.53
  • Low Estimate $-1.73
  • Prior Year $-1.12
  • Growth Rate Est. (year over year) -46.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.63 +18.24%
on 06/10/26
80.15 -1.71%
on 06/18/26
+3.60 (+4.79%)
since 05/18/26
3-Month
58.65 +34.33%
on 04/29/26
80.20 -1.77%
on 05/05/26
+16.59 (+26.68%)
since 03/18/26
52-Week
31.99 +146.26%
on 06/23/25
80.20 -1.77%
on 05/05/26
+46.05 (+140.70%)
since 06/18/25

Most Recent Stories

More News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784...

CYTK : 78.78 (+0.86%)
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE)...

CYTK : 78.78 (+0.86%)
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first...

CYTK : 78.78 (+0.86%)
Cytokinetics to Participate in June Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor...

CYTK : 78.78 (+0.86%)
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise

Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS program...

CYTK : 78.78 (+0.86%)
Cytokinetics to Hold Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026...

CYTK : 78.78 (+0.86%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2026 it granted stock options to purchase an aggregate of 20,807...

CYTK : 78.78 (+0.86%)
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)

Third Annual Muscle Biology-Focused Research Symposium  Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:...

CYTK : 78.78 (+0.86%)
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in a fireside chat...

CYTK : 78.78 (+0.86%)
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Multinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety   SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK)...

CYTK : 78.78 (+0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 83.25
2nd Resistance Point 81.70
1st Resistance Point 80.24
Last Price 78.78
1st Support Level 77.23
2nd Support Level 75.68
3rd Support Level 74.22

See More

52-Week High 80.20
Last Price 78.78
Fibonacci 61.8% 61.78
Fibonacci 50% 56.09
Fibonacci 38.2% 50.41
52-Week Low 31.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.